Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial

CONCLUSIONS: Three repeated administrations of hUCB-MSCs into the lateral ventricle via an Ommaya reservoir were feasible, relatively and sufficiently safe, and well-tolerated. Currently, we are undergoing an extended follow-up study for those who participated in a phase IIa trial where upon completion, we hope to gain a deeper understanding of the clinical efficacy of MSC AD therapy.TRIAL REGISTRATION: ClinicalTrials.gov NCT02054208. Registered on 4 February 2014. ClinicalTrials.gov NCT03172117. Registered on 1 June 2017.PMID:34521461 | DOI:10.1186/s13195-021-00897-2

Source: Cell Research - September 15, 2021 Category: Cytology Authors: Hee Jin Kim Kyung Rae Cho Hyemin Jang Na Kyung Lee Young Hee Jung Jun Pyo Kim Jung Il Lee Jong Wook Chang Seongbeom Park Sung Tae Kim Seung Whan Moon Sang Won Seo Soo Jin Choi Duk L Na Source Type: research